Be part of the knowledge.

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Therapeutic Mechanisms of Action (MOA) in MS

Review information about new and emerging treatment strategies for MS patients and how to best incorporate this information into practice.

Available credits: 0.50

Time to complete: 30 minutes


Take Post-Test

If you’ve already completed the activity.

  • Overview

    This activity is being hosted on behalf of the Global Multiple Sclerosis Academy. For more information, visit the site:

    This interactive module, led by Dr. Gavin Giovannoni, will review the current and future treatment options for treating and managing MS patients based on the mechanism of action. This education will also explore various approached to managing MS patients by drugs that module the immune system.


    As of August 2017, Cladribine was approved in Europe for the treatment of highly active relapsing multiple sclerosis (RMS). All studies presented in this education are still accurate. To learn more about this approval, click here

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty Name:
    Gavin Giovannoni, MBBCh, PhD, FCP (S.A., Neurol), FRCP, FRCPath
    Blizard Institute, Barts and the London School of Medicine and Dentistry,
    Queen Mary University, London
    Department of Neurology
    Royal London Hospital
    Barts Health NHS Trust

    Financial Relationship Disclosure
    Steering Committee: AbbVie, Biogen-Idec, Novartis, TEVA, Roche
    Consultant: Biogen-Idec, GW Pharma, Merck-Serono, Novartis, Genzyme Sanofi, Fiveprime, Ironwood, Synthon BV, Vertex Pharmaceuticals
    Clinical Advisor: Canbex


    • Sean T. Barrett has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Michael B. Montalto, PhD has nothing to disclose.
    • Lawrence Sherman has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe current and future treatment options for managing MS patients based on the mechanism of action
    • Review approaches to managing MS patients with drugs that modulate the immune system
  • Target Audience

    This activity is designed to meet the educational needs of practicing neurologist, and other healthcare professionals that treat patients with multiple sclerosis.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at

  • Commercial Support

    This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and TOPEC Global. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Global Neurology Academy you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.